Spots Global Cancer Trial Database for cholangiocarcinoma, intrahepatic
Every month we try and update this database with for cholangiocarcinoma, intrahepatic cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma | NCT03267940 | Cholangiocarcin... Cholangiocarcin... Cholangiocarcin... Gallbladder Ade... | PEGPH20 CIS GEM Atezolizumab | 18 Years - | Halozyme Therapeutics | |
| Study of GNS561 in Patients With Liver Cancer | NCT03316222 | Hepatocellular ... Cholangiocarcin... | GNS561 | 18 Years - | Genoscience Pharma | |
| Surgery for Recurrent Intrahepatic Cholangiocarcinoma | NCT04072250 | Cholangiocarcin... Recurrence Chol... Re-hepatectomy | hepatectomy | 18 Years - 75 Years | Chang Gung Memorial Hospital | |
| Nab-Paclitaxel Combined With Gemcitabine Adjuvant Chemotherapy After Radical Resection of Intrahepatic Cholangiocarcinoma | NCT04077983 | Cholangiocarcin... | combined therap... | 18 Years - 75 Years | Shanghai Zhongshan Hospital | |
| Adjuvant PD-1 Antibody in Combination With Capecitabine for Patients With ICC at High-Risk of Postoperative Recurrence | NCT04782804 | Cholangiocarcin... | Capecitabine PD-1 Antibody（T... | 18 Years - 75 Years | Fudan University | |
| Standardized CEUS Algorithms for Diagnosis of HCC - Prospective German Multicenter Study | NCT03405909 | Hepatocellular ... Cholangiocarcin... Liver Cirrhosis Liver Cancer Liver Neoplasms Liver Diseases | contrast enhanc... MRI Histology | 18 Years - | University Hospital Erlangen | |
| Adjuvant PD-1 Antibody in Combination With Capecitabine for Patients With ICC at High-Risk of Postoperative Recurrence | NCT04782804 | Cholangiocarcin... | Capecitabine PD-1 Antibody（T... | 18 Years - 75 Years | Fudan University | |
| Combined Therapy Using Oxaliplatin and Gemcitabine Chemotherapy, Lenvatinib and PD1 Antibody (JS001) for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma | NCT03951597 | Cholangiocarcin... | combined therap... | 18 Years - 75 Years | Shanghai Zhongshan Hospital | |
| Percutaneous Cholangiopancreatoscopy Registry | NCT05210322 | Biliary Stones Cholangiocarcin... Biliary Strictu... Cholelithiasis Choledocholithi... | Percutaneous ch... | 18 Years - | Johns Hopkins University | |
| Study of GNS561 in Patients With Liver Cancer | NCT03316222 | Hepatocellular ... Cholangiocarcin... | GNS561 | 18 Years - | Genoscience Pharma | |
| Cisplatin and Gemcitabine Chemotherapy and Lenvatinib for Patients With Unresectable Intrahepatic Cholangiocarcinoma | NCT04527679 | Cholangiocarcin... | GC combined Len... | 18 Years - 75 Years | Shanghai Zhongshan Hospital | |
| Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma | NCT03267940 | Cholangiocarcin... Cholangiocarcin... Cholangiocarcin... Gallbladder Ade... | PEGPH20 CIS GEM Atezolizumab | 18 Years - | Halozyme Therapeutics | |
| Percutaneous Cholangiopancreatoscopy Registry | NCT05210322 | Biliary Stones Cholangiocarcin... Biliary Strictu... Cholelithiasis Choledocholithi... | Percutaneous ch... | 18 Years - | Johns Hopkins University | |
| PD1 Antibody (Toripalimab), GEMOX and Lenvatinib Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors | NCT04506281 | Cholangiocarcin... | neoadjuvant tre... | 18 Years - 70 Years | Shanghai Zhongshan Hospital | |
| Liver Transplant for Stable, Advanced Intrahepatic Cholangiocarcinoma | NCT04195503 | Cholangiocarcin... | Liver Transplan... | 18 Years - | University Health Network, Toronto | |
| PD1 Antibody (Toripalimab), GEMOX and Lenvatinib Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors | NCT04506281 | Cholangiocarcin... | neoadjuvant tre... | 18 Years - 70 Years | Shanghai Zhongshan Hospital | |
| Expanded Access for the Treatment of Advanced Cholangiocarcinoma With ABC294640 (Yeliva ®) | NCT03414489 | Cholangiocarcin... Cholangiocarcin... Cholangiocarcin... Cholangiocarcin... Cholangiocarcin... | ABC294640 | 18 Years - | RedHill Biopharma Limited | |
| PD-L1 Antibody Combined With CTLA-4 Antibody for Patients With Advanced Intrahepatic Cholangiocarcinoma Who Progressed After Standard Treatment | NCT04634058 | Cholangiocarcin... PD-L1 CTLA4 | PD-L1 antibody ... | 18 Years - | Shanghai Zhongshan Hospital | |
| Recombinant Human Adenovirus Type 5 Plus HAIC of FOLFOX for Intrahepatic Cholangiocarcinoma | NCT05124002 | Cholangiocarcin... | Recombinant Hum... HAIC of FOLFOX | 18 Years - | Beijing Tsinghua Chang Gung Hospital | |
| Study of GNS561 in Patients With Liver Cancer | NCT03316222 | Hepatocellular ... Cholangiocarcin... | GNS561 | 18 Years - | Genoscience Pharma | |
| Liver Transplant for Stable, Advanced Intrahepatic Cholangiocarcinoma | NCT04195503 | Cholangiocarcin... | Liver Transplan... | 18 Years - | University Health Network, Toronto | |
| Adjuvant PD-1 Antibody in Combination With Capecitabine for Patients With ICC at High-Risk of Postoperative Recurrence | NCT04782804 | Cholangiocarcin... | Capecitabine PD-1 Antibody（T... | 18 Years - 75 Years | Fudan University | |
| PD1 Antibody (Toripalimab), GEMOX and Lenvatinib Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors | NCT04506281 | Cholangiocarcin... | neoadjuvant tre... | 18 Years - 70 Years | Shanghai Zhongshan Hospital | |
| Adjuvant PD-1 Antibody in Combination With Capecitabine for Patients With ICC at High-Risk of Postoperative Recurrence | NCT04782804 | Cholangiocarcin... | Capecitabine PD-1 Antibody（T... | 18 Years - 75 Years | Fudan University | |
| Two-cohort Study of Toripalimab(PD1)+Lenvatnib, or Gemox+Lenvatinib in Advanced Intrahepatic Cholangiocarcinoma | NCT04361331 | Cholangiocarcin... | Lenvatinib comb... Toripalimab com... | 18 Years - 75 Years | Shanghai Zhongshan Hospital | |
| Combined Therapy Using Oxaliplatin and Gemcitabine Chemotherapy, Lenvatinib and PD1 Antibody (JS001) for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma | NCT03951597 | Cholangiocarcin... | combined therap... | 18 Years - 75 Years | Shanghai Zhongshan Hospital | |
| Expanded Access for the Treatment of Advanced Cholangiocarcinoma With ABC294640 (Yeliva ®) | NCT03414489 | Cholangiocarcin... Cholangiocarcin... Cholangiocarcin... Cholangiocarcin... Cholangiocarcin... | ABC294640 | 18 Years - | RedHill Biopharma Limited | |
| Percutaneous Cholangiopancreatoscopy Registry | NCT05210322 | Biliary Stones Cholangiocarcin... Biliary Strictu... Cholelithiasis Choledocholithi... | Percutaneous ch... | 18 Years - | Johns Hopkins University | |
| Detecting Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma (LyMIC) | NCT06381648 | Cholangiocarcin... Cholangiocarcin... Cholangiocarcin... Cholangiocarcin... | LyMIC (Lymph No... | 18 Years - | City of Hope Medical Center | |
| Cisplatin and Gemcitabine Chemotherapy and Lenvatinib for Patients With Unresectable Intrahepatic Cholangiocarcinoma | NCT04527679 | Cholangiocarcin... | GC combined Len... | 18 Years - 75 Years | Shanghai Zhongshan Hospital | |
| PD1 Antibody (Toripalimab), GEMOX and Lenvatinib Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors | NCT04506281 | Cholangiocarcin... | neoadjuvant tre... | 18 Years - 70 Years | Shanghai Zhongshan Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
